On September 7, 2021, with the end of the final meeting, Sichuan Qingmu Pharmaceutical Co., Ltd. (hereinafter referred to as Qingmu pharmaceutical), a wholly-owned subsidiary of Chengdu Easton Biopharmaceutical, successfully passed the FDA cGMP on-site inspection.
This FDA on-site inspection is the first time Qingmu pharmaceutical has accepted the cGMP on-site inspection of official drugs in Europe and America, which marks that the company's GMP management has reached an international high level, provides a new opportunity for the company to further expand the American API market, has a positive impact on the expansion of the global API market, and is an important milestone in the company's internationalization strategy, It has important practical significance and strategic value!










(All Rights Reserved)